within Pharmacolibrary.Drugs.ATC.N;

model N05AC04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.9999999999999996e-06,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AC04</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pipotiazine is a typical antipsychotic drug belonging to the phenothiazine class, primarily used for the treatment of schizophrenia and other psychotic disorders. It is often given as a long-acting intramuscular injection in the form of pipotiazine palmitate. Its use has declined in many countries due to the advent of atypical antipsychotics, but it may still be available in some regions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult patients based on general properties of phenothiazine antipsychotics and available clinical summaries. No publication found with detailed compartmental pharmacokinetics for pipotiazine.</p><h4>References</h4><ol><li><p>Spanarello, S, &amp; La Ferla, T (2014). The pharmacokinetics of long-acting antipsychotic medications. <i>Current clinical pharmacology</i> 9(3) 310–317. DOI:<a href=&quot;https://doi.org/10.2174/15748847113089990051&quot;>10.2174/15748847113089990051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23343447/&quot;>https://pubmed.ncbi.nlm.nih.gov/23343447</a></p></li><li><p>Altamura, AC, et al., &amp; Mundo, E (2003). Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. <i>Drugs</i> 63(5) 493–512. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363050-00004&quot;>10.2165/00003495-200363050-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12600227/&quot;>https://pubmed.ncbi.nlm.nih.gov/12600227</a></p></li><li><p>Gallant, DM, et al., &amp; Guerrero-Figueroa, R (1975). Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients. <i>Diseases of the nervous system</i> 36(4) 193–196. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1090427/&quot;>https://pubmed.ncbi.nlm.nih.gov/1090427</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AC04;
